Lakefront Biotherapeutics (LKFT) Gross Margin (2021 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Gross Margin of 25.95% for Q1 2026, down 5574.0% year-on-year from 0.47% in Q1 2025, and down 74.03% on a QoQ basis from 99.95% in Q4 2025.
Lakefront Biotherapeutics (LKFT) Gross Margin (2021 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Gross Margin for 6 consecutive years, with 25.95% the latest figure, recorded in Q1 2026.
- Quarterly Gross Margin fell 5574.0% year-over-year to 25.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.01% (up 1228.0% YoY) and the FY2025 annual result came in at 97.33%, up 997.0% from the prior year.
- Gross Margin fell to 25.95% in Q1 2026 per LKFT's latest filing, from 99.95% in the prior quarter.
- Over the last five years, Gross Margin for LKFT reached as high as 99.95% in Q4 2025 and fell as low as 25.95% in Q1 2026.
- A 5-year average of 86.65% and a median of 90.62% in 2023 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2025 — Gross Margin surged 1473 bps — and 2026, when it slumped 5574 bps.
- Year by year, Gross Margin stood at 97.71% in 2022, then slipped by 14 bps to 83.97% in 2023, then rose by 1 bps to 85.22% in 2024, then climbed by 17 bps to 99.95% in 2025, then sank by 74 bps to 25.95% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 25.95%, 99.95%, and 84.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | 25.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.95% |
| Dec 31, 2025 | 99.95% |
| Sep 30, 2025 | 84.76% |
| Jun 30, 2025 | 92.79% |
| Mar 31, 2025 | 81.69% |
| Dec 31, 2024 | 85.22% |
| Sep 30, 2024 | 90.94% |
| Jun 30, 2024 | 98.95% |
| Mar 31, 2024 | 95.92% |
| Dec 31, 2023 | 83.97% |
| Sep 30, 2023 | 90.62% |
| Jun 30, 2023 | 92.96% |
| Mar 31, 2023 | 93.90% |
| Dec 31, 2022 | 97.71% |
| Sep 30, 2022 | 90.28% |
| Jun 30, 2022 | 87.67% |
| Mar 31, 2022 | 79.79% |
| Dec 31, 2021 | 99.59% |
| Sep 30, 2021 | 88.52% |
| Jun 30, 2021 | 99.96% |